Recognition of non-operating income and extraordinary gain
BrightPath Biotherapeutics Co.,Ltd. (the Company)
Fluctuations in foreign exchange rates, the sale of fixed assets, and the reversal of stock acquisition rights
Foreign exchange gain of ¥1,077 thousand (non-operating income), gain on sale of fixed assets of ¥659 thousand (extraordinary income), and gain on reversal of stock acquisition rights of ¥15,342 thousand (extraordinary income)
The first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
Please refer to the “Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)” announced today.
Please refer to the “Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)” announced today for the impact on financial results.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating income and extraordinary gain |
| Date of occurrence | Recorded during the first quarter accounting period of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026). The individual dates of occurrence are Not disclosed. |
| Subject Entity | BrightPath Biotherapeutics Co.,Ltd. (the Company) |
| Cause | Fluctuations in foreign exchange rates, the sale of fixed assets, and the reversal of stock acquisition rights |
| Amount of Impact on Business Performance | Foreign exchange gain of ¥1,077 thousand (non-operating income), gain on sale of fixed assets of ¥659 thousand (extraordinary income), and gain on reversal of stock acquisition rights of ¥15,342 thousand (extraordinary income) |
| Accounting period in which recognized | The first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | Please refer to the “Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)” announced today. |
| Outlook | Please refer to the “Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)” announced today for the impact on financial results. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Foreign exchange gains resulting from fluctuations in foreign exchange rates, the sale of fixed assets, and the reversal of stock acquisition rights.